Key result
Non-White and White patients show similar 90-day major event rates during supported high-risk PCI.
Why the study?
Racial disparities in coronary artery disease persist for non-White populations, and poor outcomes following PCI remain particularly common for Black patients compared with White patients.
Does race (non-White vs White) or type of mechanical circulatory support (Impella 2.5 pLVAD vs IABP) affect 90-day major adverse events in patients undergoing high-risk percutaneous coronary intervention?
RCT (n=425)
Randomization not stratified by race (prespecified analysis of the PROTECT II randomized trial)
Does race (non-White vs White) or type of mechanical circulatory support (Impella 2.5 pLVAD vs IABP) affect 90-day major adverse events in patients undergoing high-risk percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
In the PROTECT II trial, non-White patients had similar overall 90-day outcomes after hemodynamically supported high-risk PCI compared with White patients, and experienced significantly fewer major adverse events when supported with Impella 2.5 pLVAD compared with IABP.
Racial disparities persist for non-White populations regarding access, treatment, and outcomes for coronary artery disease.1,2 These may have been relieved, in part, by Medicaid expansion through the Affordable Care Act3; however, poor outcomes following percutaneous coronary intervention (PCI) persist, particularly for Black patients. A recent meta-analysis of 10 coronary stent randomized controlled trials found that Black patients had higher rates of diabetes, dyslipidemia, hypertension, and smoking, and a 1.28 hazard ratio for major adverse cardiac events at 5 years compared with White patients (P =.01).
No takes yet. Share an insight, caveat, or question.
Fuller et al. (2023) conducted an RCT in High-risk percutaneous coronary intervention requiring mechanical circulatory support (n=425). Non-White race (and Impella 2.5 percutaneous left ventricular assist device [pLVAD] vs IABP within racial groups) vs. White race (and intra-aortic balloon pump [IABP]) was evaluated on Major adverse events (MAEs: composite of death, MI, stroke/TIA, repeat revascularization, cardiac or vascular operation, acute renal dysfunction, severe hypotension, CPR/ventricular arrhythmia requiring cardioversion, increase in aortic insufficiency >=1 grade, or angiographic failure) at 90 days (p=0.53).
Synapse has enriched 10 related papers. Consider them for comparative context: